Flagship Pioneering’s Senda Bio secures $123M for new ‘programmable medicines’

Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.

Leave a Comment

Your email address will not be published.